Background {#Sec1}
==========

DNA methylation, an epigenetic process characterized by the addition of a methyl group to a DNA molecule influences the expression of genes \[[@CR1], [@CR2]\]. It is associated with several health conditions including cancer, metabolic, neurological, psychiatric, and autoimmune disorders \[[@CR1]--[@CR5]\]. A greater portion of DNA methylation in humans takes place in regions called CG or CpG sites, where a cytosine precedes a guanine nucleotide \[[@CR1], [@CR2]\]. Due to its epigenetic nature, DNA methylation is associated with several environmental factors including cigarette smoking, exercise, and alcohol drinking, among others \[[@CR6], [@CR7]\].

The gene, aryl hydrocarbon receptor repressor (AHRR), mediates the metabolism of xenobiotic particles like toxic cigarette smoke components \[[@CR8], [@CR9]\]. This gene is located on chromosome 5 which is believed to possess several tumor suppressor genes \[[@CR10], [@CR11]\]. Blood AHRR methylation (especially at cg0557592) is inversely associated with both smoking \[[@CR4], [@CR5], [@CR8], [@CR9], [@CR12]--[@CR16]\] and lung cancer \[[@CR4], [@CR12], [@CR13]\].

Cigarette smoke and PM~2.5~ are both inhalable carcinogenic factors composed of a complex mixture of chemicals, one of which is polycyclic aromatic hydrocarbons (PAHs) \[[@CR11], [@CR17]--[@CR19]\]. PM-related PAHs pose most of the health problems in humans \[[@CR20]\]. Exposure to PAHs is capable of activating the aryl hydrocarbon receptor (AHR) \[[@CR17], [@CR21]\] and is thought to be responsible for variations in smoking-related AHRR methylation \[[@CR9]\]. Even though AHR activation is associated with particulate matter \[[@CR22], [@CR23]\], research on the association between methylation at cg05575921 (AHRR) and PM~2.5~ is limited. In a cross-sectional study, AHRR (cg05575921) hypomethylation in non-smokers was associated with exposure to second-hand smoke (SHS) but not PM~2.5~ \[[@CR24]\]. Moreover, in a recent review on DNA methylation and environmental factors, several studies were listed to have demonstrated associations between AHRR hypomethylation and tobacco smoke. However, none was listed to have demonstrated an association between AHRR hypomethylation and exposure to air pollution or PAHs \[[@CR25]\].

In a study conducted in Taiwan, PM~2.5~ was used as a proxy marker for PAHs \[[@CR20]\]. PM~2.5~ concentrations in northern Taiwan are lower than in central and southern areas \[[@CR26]--[@CR29]\]. Because PAHs are present in both PM~2.5~ and cigarette smoke, AHRR (cg05575921) methylation in smokers might be comparable with that in non-smokers exposed to PM~2.5~. Therefore, we used an epigenetic approach to investigate the pattern of blood methylation at cg05575921 in non-smoking Taiwanese adults residing in areas with different PM~2.5~ concentrations.

Results {#Sec2}
=======

Table [1](#Tab1){ref-type="table"} shows the general characteristics of study participants. There were 708 participants comprising 279 men (mean age = 49.42 ± 11.76 years) and 429 women (mean age = 49.49 ± 10.97 years). The mean (± SD) methylation level at cg05575921 was 0.83604 ± 0.00154. In general, 244, 121, 134, and 209 participants resided in the northern, north-central, central, and southern areas, respectively. Table [2](#Tab2){ref-type="table"} shows the mean (± SD) concentrations of PM~2.5~ (μg/m^3^) from 2006 to 2011 in the study areas. These concentrations were 27.32 ± 4.34, 28.65 ± 2.13, 35.72 ± 3.75, and 39.81 ± 2.10 μg/m^3^ for the northern, north-central, central, and southern areas, respectively. Table [3](#Tab3){ref-type="table"} shows the association between living in PM~2.5~ areas and AHRR (cg05575921) methylation. With the northern area as the reference, residing in north-central, central, and southern areas was associated with lower blood methylation levels at cg05575921. When SHS was included in the analysis, the regression coefficients (*β*) were − 0.00274 (*P* = 0.503), − 0.01003 (*P* = 0.009), and − 0.01480 (*P* \< 0.001), respectively (Table [3](#Tab3){ref-type="table"}, model 1). That is, the blood methylation levels in participants residing in north-central, central, and southern areas were lower when compared to those in the northern area. The differences were − 0.00274, − 0.01003, and − 0.01480, respectively. After SHS was excluded from the analysis, the regression coefficients (*β*) were − 0.00028 (*P* = 0.947), − 0.01069 (*P* = 0.009), and − 0.01487 (*P* \< 0.001), respectively (Table [3](#Tab3){ref-type="table"}, model 2). Even though methylation levels in participants who lived in north-central areas were not statistically significant, the test for linear trend was statistically significant (*P* trend \< 0.001) in both models (Table [3](#Tab3){ref-type="table"}, models 1 and 2). The mean PM~2.5~ concentration from 2006--2011 was significantly associated with lower blood AHRR methylation levels at cg05575921 (Table [4](#Tab4){ref-type="table"}). A unit increase in PM~2.5~ concentration was associated with 0.00115 (*P* \< 0.001) lower methylation when SHS was included in the analysis (Table [4](#Tab4){ref-type="table"}, model 1). Similarly, a unit increase in PM~2.5~ concentration was associated with 0.00124 (*P* \< 0.001) lower methylation after SHS was excluded from the analysis (Table [4](#Tab4){ref-type="table"}, model 2). Spearman analysis showed a significant negative correlation (β = − 0.78329; *P* \< 0.001) between PM~2.5~ concentration (μg/m^3^) and mean methylation levels (Additional file [1](#MOESM1){ref-type="media"}). The associations between PM~2.5~ and 176 sites in the AHRR promoter region are shown in Additional file [2](#MOESM2){ref-type="media"}. In addition to cg05575921, some other sites that were significantly associated with PM~2.5~ include cg26703534 (*β* = − 0.00127; *P* \< 0.001), cg25648203 (*β* = − 0.00078; *P* \< 0.001), and cg21161138 (*β* = − 0.00046; *P* = 0.007). Table 1General characteristics of study participants (2008--2015)VariableMenWomenAll participants*n* = 279*n* = 429*P* value*n* = 708cg05575921 (*β* value)0.84260 ± 0.037400.82650 ± 0.03920\< .0010.83626 ± 0.03892Area0.833 Northern92 (32.97%)152 (35.43%)244 (34.46%) North-Central46 (16.49%)75 (17.48%)121 (17.09%) Central54 (19.35%)80 (18.65%)134 (18.93%) Southern87 (31.18%)122 (28.44%)209 (29.52%)Age (years)49.42 ± 11.7649.49 ± 10.970.92649.46 ± 11.28Alcohol Drinking\< .001 No251 (89.96%)423 (98.60%)674 (95.20%) Former7 (2.51%)3 (0.70%)10 (1.41%) Current21 (7.53%)3 (0.70%)24 (3.39%)Exercise No157 (56.27%)240 (55.94%)0.931397 (56.07%) Yes122 (43.73%)189 (44.06)311 (43.93%)BMI (kg/m^2^)23.52 ± 3.5724.95 ± 3.44\< .00124.08 ± 3.59SHS0.598 No251 (89.96%)391 (91.14%)642 (90.68%) Yes28 (10.04%)38 (8.86%)66 (9.32%)Continuous variables are presented as mean ± SD while categorical variables are presented as numbers (%)*SD* standard deviation, *SHS* second-hand smokeTable 2Mean (± SD) concentrations of PM~2.5~ (μg/m3) from 2006--2011 in the study areasArea*n*2006--2011200620072008200920102011Northern1827.32 ± 4.3427.43 ± 5.0328.69 ± 5.3927.33 ± 5.4825.96 ± 5.3225.98 ± 5.3726.61 ± 5.30North-Central1228.65 ± 2.1329.81 ± 2.3429.39 ± 2.9829.75 ± 2.5928.74 ± 2.4726.93 ± 1.8227.28 ± 2.84Central1635.72 ± 3.7536.27 ± 3.2036.64 ± 3.8135.56 ± 3.7637.67 ± 3.6334.83 ± 3.0236.17 ± 5.34Southern739.81 ± 2.1040.75 ± 2.3041.00 ± 2.9141.62 ± 3.3740.08 ± 3.4136.81 ± 3.1538.05 ± 4.04*SD* standard deviation, *n* number of monitoring stationsTable 3Multiple linear regression showing the association between living in PM~2.5~ areas and AHRR (cg05575921) methylationVariableModel 1Model 2*βP* value*βP* valueArea (reference: Northern)-------- North-Central− 0.002740.503− 0.00280.947 Central− 0.010030.009− 0.010690.009 Southern− 0.01480\< .001− 0.01487\< .001 *P* trend\< .001\< .001Sex (reference: women) Men− 0.01491\< .001− 0.01413\< .001Age− 0.000230.085− 0.000220.114Alcohol Drinking (reference: no) Former− 0.010410.358− 0.014970.238 Current− 0.005320.475− 0.004240.609Exercise (reference: no) Yes− 0.001990.490− 0.001800.552BMI− 0.000090.819− 0.000050.906SHS (reference: no)---- Yes− 0.001190.796----*Model 1* included SHS in the analysis, *model 2* excluded SHS from the analysis, *SHS* second-hand smokeTable 4Multiple linear regression showing the association between mean PM~2.5~ (μg/m3) from 2006--2011 and AHRR (cg05575921) methylationVariableModel 1Model 2*βP* value*βP* valuePM~2.5~− 0.00115\< .001− 0.00124\< .001Sex (reference: women) Men− 0.01489\< .001− 0.01416\< .001Age− 0.000230.083− 0.000220.116Alcohol Drinking (reference: no) Former− 0.010430.357− 0.014940.238 Current− 0.005340.473− 0.004300.603Exercise (reference: no) Yes− 0.001960.495− 0.001830.545BMI− 0.000070.8440.000030.942SHS (reference: no)---- Yes− 0.001150.802----*Model 1* included SHS in the analysis, *model 2* excluded SHS from the analysis, *SHS* second-hand smoke

Discussion {#Sec3}
==========

Studies on the association between AHRR methylation and sources of polycyclic aromatic hydrocarbon (PAH) other than smoking are limited. To our knowledge, the current study is the first to assess blood AHRR methylation in non-smokers residing in areas with different concentrations of PM~2.5~. In general, PM~2.5~ was inversely associated with blood AHRR (cg05575921) methylation. Compared with the northern area, living in north-central, central, and southern areas was associated with lower blood AHRR methylation levels at cg05575921.

Living in areas with higher PM~2.5~ concentrations has been associated with greater exposure to PAH \[[@CR20]\]. Particulate matter-related PAHs have been reported as potential activators of AHR \[[@CR17]\]. PM~2.5~ and cigarette smoke both contain PAHs which can induce AHRR methylation \[[@CR11]\]. Moreover, they are both inhalable and carcinogenic \[[@CR19]\]. Several studies have explored the association between PM~2.5~ and DNA methylation in blood \[[@CR23], [@CR30]\] and placenta \[[@CR31]\]. Nonetheless, emphasis has not been laid on blood AHRR methylation in non-smokers. In light of this, we investigated the association between living in PM~2.5~ areas and AHRR methylation at cg05575921 in non-smokers. We adjusted for exposure to SHS since significant inverse associations have been found between methylation at cg05575921 and exposure to SHS in non-smokers \[[@CR24]\].

Cg05575921 was selected because it has been shown to be highly sensitive and specific in identifying and distinguishing smoking status as well as tracking trends in smoking termination and reduction \[[@CR12], [@CR15], [@CR32]--[@CR34]\]. For instance, current smokers showed the highest hypomethylation compared to former and or non-smokers \[[@CR4], [@CR5], [@CR13]--[@CR16]\]. Moreover, this methylation site has been shown to be the most statistically significant smoking-related site in several original investigations \[[@CR13], [@CR16], [@CR35]--[@CR38]\] and a meta-analysis \[[@CR39]\].

In our study, it was hypothesized that blood methylation patterns at cg05575921 (AHRR) in non-smokers residing in areas with different PM~2.5~ concentrations might be similar to those observed based on smoking status. As expected, the results were similar to those from several studies that were conducted among non-, former, and current smokers \[[@CR4], [@CR5], [@CR13]--[@CR16]\]. That is, blood methylation levels at cg05575921 in non-smokers residing in Southern Taiwan were lowest followed by Central and Northern Taiwan with significant linear trends. The regression coefficients were − 0.00028, − 0.01069, and − 0.01487 for north-central, central, and southern areas, respectively. Previous studies have reported regression coefficients of 0.83, 0.79, and 0.59 for never, former, and current smokers \[[@CR5]\] and 0.878, 0.829, and 0.772 for non-, light, and heavy smokers, respectively \[[@CR16]\]. Moreover, the methylation extent was 64, 60, and 50 % among never, former, and current smokers \[[@CR4]\]. PM~2.5~ levels are higher in Southern and Central compared to Northern Taiwan \[[@CR26]--[@CR29]\]. There are many heavy industries (e.g., petrochemical plants) in these areas \[[@CR27], [@CR28], [@CR40]\]. Emissions from these industries are believed to be one of the main sources of PM~2.5~- and PM~2.5~-bound PAHs \[[@CR41]--[@CR43]\]. Higher concentrations of PM~2.5~-bound PAHs have also been reported in the industrial cities of Christchurch and Guadalajara in New Zealand \[[@CR43], [@CR44]\] and Mexico \[[@CR43], [@CR45]\].

Some of the merits of our study include (1) the relatively larger sample size, (2) the adjustment for exposure to SHS to avoid its confounding effect, and (3) stratification of participants into four areas known for different PM~2.5~ levels. However, the study is limited in that DNA methylation was determined using the Illumina Infinium MethylationEPIC BeadChip which covers 850,000 methylation sites. Even though this microarray has been validated as a very reliable genomic platform for determining DNA methylation patterns in the human genome \[[@CR46]\], validation experiments were not performed to confirm our findings. Therefore, future investigations to support our results are recommended. Moreover, functional correlation between cg05575921 methylation and AHRR mRNA gene expression was not evaluated in this study. Furthermore, the actual concentrations of PM~2.5~ in individuals could not be determined since there are no validated tools for individual exposure estimates. Air quality indices from nearby monitoring stations are usually used for air pollution estimation \[[@CR47]\]. In the current study, the number of monitoring stations corresponding to the participants' residence was relatively small. This is because some counties involved in the study do not have monitoring stations; hence, PM~2.5~ estimates were not available for participants living in such areas. However, we think our results are plausible because variations in PM~2.5~ concentration in various areas in Taiwan are well known \[[@CR26]--[@CR29]\]. Moreover, the inclusion of mean PM~2.5~ concentration from the study areas (2006--2011) into our regression model showed significant inverse associations between PM~2.5~ and blood methylation at cg05575921 (AHRR). The fact that other environmental factors would have also accounted for this association cannot be completely rolled out. However, the emphasis on PM~2.5~ is because it contains PAHs which are related to AHRR. Exposure to PAHs is believed to cause smoking-related AHRR methylation \[[@CR9]\]. Moreover, PM~2.5~ is a serious problem in Taiwan and PM-related PAHs pose most of the health problems in humans \[[@CR20]\].

Conclusion {#Sec4}
==========

In conclusion, living in PM~2.5~ areas was inversely associated with blood AHRR methylation levels at cg05575921. Compared with Northern Taiwan (which has the lowest PM~2.5~ levels), living in North-Central, Central, and Southern Taiwan was associated with lower blood AHRR methylation levels at cg05575921. The methylation levels were lowest in those residing in the southern area (which has the highest PM~2.5~) levels followed by central and north-central areas. Moreover, PM~2.5~ was inversely associated with methylation levels at cg05575921 when it was included in the regression model. AHRR (cg05575921) methylation might serve as an indicator of differential exposures to PM~2.5~ and lung cancer which is also a PM~2.5~-related disease. Further investigations to confirm these findings are recommended.

Methods {#Sec5}
=======

Data source {#Sec6}
-----------

Data used in the current study were obtained from the Taiwan Biobank which was founded in 2005. The biobank aims at undertaking large-scale cohort and case-control studies through the combination of genetic and medical information \[[@CR48], [@CR49]\]. The information collected is currently serving as one of the cornerstones of medical research in Taiwan. It is hoped that the identification of disease risk factors and the underlying mechanisms would lead to the development of better treatments and prevention strategies, hence, reduced medical costs \[[@CR48], [@CR49]\]. As a result, the health of the population would probably be promoted and improved.

Information about recruitment in the Taiwan Biobank project is obtained through brochures, posters, media, and websites. Interested volunteers are asked to provide their contact information. These volunteers are contacted to confirm their willingness to participate, and those who fulfill the recruitment requirements (strictly Taiwanese aged 30--70 years with no personal history of cancer) are assigned to specific recruitment centers. Currently, the biobank comprises 29 recruitment centers with each city or county having at least 1 center \[[@CR49]\]. Before data are collected, all the participants sign a letter of consent.

Data collection {#Sec7}
---------------

Data were collected by trained medical researchers through questionnaires (e.g., residence, sex, age, smoking, alcohol drinking, exercise habits, and exposure to SHS), physical examination (e.g., weight and height), and blood examination (e.g., DNA methylation). Participants were considered as non-smokers if they reported to have never smoked or have not continuously smoked for at least 6 months. Former smokers were those who reported to have continuously smoked for at least 6 months but were currently not smoking. Current smokers were those who reported to have continuously smoked for at least 6 months and were currently smoking. Participants were considered non-drinkers if they did not drink or drank less than 150 cc of alcohol per week continuously for 6 months. Former drinkers were those who abstained from alcohol for more than 6 months while current drinkers were those who drank at least 150 cc of alcohol per week continuously for 6 months. Exercise habits were categorized under "yes" if participants reported a habit of exercising at least three times per week (each exercise time \> 30 min) and under "no" if they did not exercise at least three times per week. Individuals considered to be exposed to SHS were those who reported being exposed to SHS for at least 5 minutes per hour. BMI was derived from weight and height as BMI = weight (kg)/height (m^2^).

DNA was extracted from whole blood using an automated extraction machine called chemagic^TM^ Prime^TM^ instrument. DNA length was checked using Fragment Analyzer (Agilent). Its quality was assessed using the ratio of absorbance at 260/280 with the purity index set as 1.6--2.0. The samples that passed quality control were stored at − 80 °C for long-term use. DNA methylation was determined using the Illumina Infinium MethylationEPIC BeadChip which has been previously described \[[@CR50]--[@CR52]\]. In brief, DNA samples were treated with sodium bisulfite conversion using the EZ DNA Methylation Kit (Zymo Research, CA, USA). Data quality control was performed based on the Illumina® GenomeStudio® Methylation Module v1.8 \[[@CR53]\]. Samples with *P* value \> 0.05 or bead count \< 3 were removed. Dye bias across batches was adjusted by normalization and background correction was performed. Outliers were removed using the median absolute deviation method. The methylation level at each CpG site was determined using *β* values. The *β* values were derived using the formula *β* = *M*/(*M* + *U*), where *M* = methylated intensity and *U* = unmethylated intensity.

Study participants {#Sec8}
------------------

Data used in the current study were retrieved from the Taiwan Biobank dataset (2008--2015). A total of 1142 individuals aged between 30 and 70 years with no personal history of cancer were initially enrolled. We excluded 301 current and former smokers, as well as 133 individuals who did not live in the study area (Fig. [1](#Fig1){ref-type="fig"}) from the study. The final sample included 708 non-smoking participants consisting of 279 men and 429 women.Fig. 1Map showing the study areas and the location of monitoring stations

The study area was categorized into Northern (Taipei and New Taipei Cities), North-Central (Taoyuan and Hsinchu Cities, Hsinchu, Miaoli, and Taoyuan Counties), Central (Taichung City, Nantou, Changhua, and Yunlin Counties), and Southern Taiwan (Chiayi County, Tainan, and Chiayi Cities). These areas are well known for varying PM~2.5~ levels. That is, PM~2.5~ levels increase as one moves from the north through the center towards the south of Taiwan \[[@CR26]--[@CR29]\]. Overall, there were 244, 121, 134, and 209 participants residing in the northern, north-central, central, and southern areas, respectively. The number of monitoring stations was 18 for the northern, 12 for the north-central, 16 for the central, and 7 for the southern area. In this study, we used the average PM~2.5~ levels (2006--2011) of the monitors of each area (northern, north-central, central, and southern areas) to estimate the PM~2.5~ exposure of participants. The location of participants and monitoring stations is shown in Fig. [1](#Fig1){ref-type="fig"}. The current study was approved by the Chung Shan Medical University Institutional Review Board (CS2-17070).

Statistical analysis {#Sec9}
--------------------

Cell-type heterogeneity was corrected using the Reference-Free Adjustment for Cell-Type composition (ReFACTor) approach with the R software described by Rahmani and colleagues \[[@CR54]\]. The association between blood methylation levels at cg05575921 and living in PM~2.5~ areas was determined using multiple linear regression analysis. Adjustments were made for sex, age, alcohol drinking, exercise, BMI, exposure to SHS, and cell type composition \[[@CR54]\]. The inclusion of sex, age, alcohol drinking, exercise, and BMI as confounders is because they are common factors that have been associated with health. Moreover, DNA methylation predictors have been shown to correlate with these factors \[[@CR55]\]. For instance, in previous studies, older age was significantly associated with lower cg05575921 methylation \[[@CR24]\] and increased PM~2.5~-related mortality \[[@CR56]\]. The male sex was significantly associated with lower cg05575921 methylation \[[@CR24]\] while the female sex was significantly associated with an increased risk of PM~2.5~-related mortality \[56\]. The regression analysis was performed with the SAS 9.3 software (SAS Institute, Cary, NC).

Additional files
================

 {#Sec10}

Additional file 1:Spearman correlation between PM~2.5~ concentrations (μg/m^3^) and mean methylation levels (beta values) in the northern, north-central, central, and southern areas. The methylation beta values decrease as PM~2.5~ levels increase. (DOCX 40 kb) Additional file 2:AHRR CpG sites significantly associated with PM~2.5.~ (DOCX 20 kb)
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